CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Sorafenibdrug
Likely dose
Sorafenib 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00414388
NCT00414388Phase 2Completed
CompareCT.gov

Phase I/II Study to Evaluate the Ability of Sorafenib in Overcoming Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer (AIPC)

Oncology Specialists, S.C.·interventional·Posted Dec 21, 2006·Updated Apr 7, 2014

In Brief

A Phase 2 clinical trial evaluating Sorafenib for Prostate Cancer. Completed, enrolled 22 participants across 2 sites.

Detailed Summary

The primary objective of this study is to evaluate the safety of combining Sorafenib and chemotherapy (mitoxantrone or docetaxel) in patients with AIPC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 21, 2006
Enrollment StartDec 1, 2006
Primary CompletionSep 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.5 years ago

Interventions

Sorafenibdrug

400mg twice daily